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Background: Asthma treatment per Global Initiative for Asthma (GINA) guidelines
targets airway remodeling and achievement of normal lung function.
Objective: To study inhaled steroid therapy on airway remodeling and achievement
of normal lung function.
Subjects and set up: Asthmatic patients were followed over 5 years .The children
were divided into two groups. Group I (148 children-treated group) consisted of all
the children using inhaled steroids on a regular basis and group II (50 children-
untreated group) included patients with mild intermittent asthma who did not use
inhaled steroids and were treated with bronchodilators as needed. Detailed
medication and compliance history were recorded and the children underwent
regular pre- and post-bronchodilator spirometry and physician examination.
Results: The incidence of airways remodeling as defined by the low FEV1/FVC post-
bronchodilator was markedly increased over the 5-year period in the untreated
group compared to the treated group. In the treated group the FEV1/FVC ratio post-
bronchodilator decreased from 35% to 20.9% (Po0:009%) compared with the
untreated group where the number of children with low FEV1/FVC post-
bronchodilator increased from 10% to 28% by the end of the study period.
Conclusion: Patients with mild asthma who do not receive regular inhaled steroids
are at increased risk for airway remodeling. Therefore, we recommend that children
with mild intermittent asthma undergo regular pulmonary function testing and that
if any deterioration is detected in the FEV1/FVC ratio post-bronchodilators;
preventative inhaled corticosteroid therapy be initiated.
& 2005 Elsevier Ltd. All rights reserved.Elsevier Ltd. All rights reserved.
6745261; fax +972 8 6745362.
.com (H.S. Bibi).
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Asthma is the most common chronic airway disease
in children. Treatment protocols for asthma are
well defined and have been in place for a number of
years.
These protocols are designed to control and
prevent airways inflammation, airways hyper re-
sponsiveness and airway remodeling.1 Chronic air-
way inflammation leads to basement membrane
thickening, sub epithelial collagen deposition and
smooth muscle and mucous gland hypertro-
phy—otherwise known as airway remodeling.2
While control of acute asthma signs and symp-
toms has been well documented, prevention of
airways remodeling presents a greater challenge.
The most accurate method to determine airways
remodeling is by performing a biopsy of the
airways, which is an invasive process. The trend
in medicine today is to move away from invasive
procedures wherever similar results and informa-
tion can be obtained in a noninvasive manner.
Rasmussen et al.3 have shown that airway remodel-
ing is demonstrated by a low FEV1/FVC ratio post-
bronchodilator. A low FEV1/FVC ratio post-bronch-
odilator is highly suggestive of airway remodeling.
Using data obtained by respiratory function testing
at a large asthma clinic, we set out to determine
whether airway remodeling occurred in patients
with mild intermittent asthma. This group is of
particular interest as current practice guidelines do
not recommend preventive anti-inflammatory med-
ication for children with mild intermittent asthma.Methods
Study group formation and inclusion criteria
This study was a historical prospective study.
Asthmatic patients at a large regional pediatric
pulmonology clinic were followed for a period of 5
years. All the children who participated in this
study were patients with asthma, diagnosed and
treated according to current GINA guidelines.4 The
study was approved by the hospital ethics commit-
tee. Inclusion criteria for the study included: (1)
Regular Clinic visits for at least 5 years. (2) Detailed
history including medication and compliance in-
formation. (3) Spirometry pre- and post-broncho-
dilators.
Only those children that fulfilled our inclusion
criteria and maintained the same asthma grade
throughout the 5-year time frame were included.
Each patient was examined at the end of the studyand the data was re-checked. Informed consent
was obtained for the study.
The children were divided into two groups. Group
I, the treated group consisted of all the children
using inhaled steroids on a regular basis and group II
the untreated group, were children with mild
intermittent asthma who did not use inhaled
steroids and were treated with bronchodilators as
needed.
Treatment was based on clinical status. The
pulmonary function tests (PFTs) were an additional
measure of airway status. All the children from the
untreated group used beta 2 agonists as needed and
had both the FEV1 and the ratio of FEV1/VC within
the widely accepted normal range for children with
mild intermittent asthma throughout the entire
study period.
Any child whose status changed and whose
treatment needed to be adapted during the
study period was excluded. The asthmatic
children were evaluated once every 3 months
over a 5-year period by the same physician.
Detailed medication and compliance history were
recorded and the children underwent regular pre-
and post-bronchodilator spirometry and physician
examination.Pulmonary function tests
PFTs were performed using a Vitalograph Spirom-
eter (Vitalograph Ltd., Birmingham, UK) according
to ATS guidelines.5 The same technician was
responsible for spirometry over the entire study
period. The pulmonary function of each child was
measured at the beginning and end of the study in
the same month of the year to overcome seasonal
influences. PFT data included FEV1/FVC and the
ratio of FEV1/FVC pre- and post-bronchodilators.
An increase of FEV1 of 10% or more was used to
determine airway hyper-responsiveness.3 Atopic
status to 10 common allergies was determined
using skin prick tests.6 Low FEV1/FVC ratio (without
prior use of bronchodilators) was defined as below
80%.
Three thousand five hundred and forty three
healthy children with no previous history of asthma
and no reported wheezing participated in a lung
health study in the Ashkelon region7 to determine
normal values. Age and sex specific lower limits of
‘‘normal’’ post-bronchodilator FEV1/VC ratio were
used to assess the presence of airways remodeling.
The mean ratio minus 1.96 SD was used to delimit
the lowest FEV1/VC ratio in the normal population.
The mean ratio for the same age was 88.9% and the
mean minus 1.96 SD was 81.8%.
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Data was evaluated using w2 analysis of variance for
contingent groups. Student t-test was performed as
indicated and correlation was calculated with
Spearman Rank Order Po0:05 set as statistical
significance. Logistic regression using SPSS& for
Windowss computer software (SPSS Inc., Chicago,
Illinois) was used to evaluate the effect of the
independent variables, adjusting for possible con-
founding factors. These variables included: base-
line FEV1/FVC; decrease AHR at the end of the
study period; parental cigarette smoking; positive
allergic skin test; dog or cat at home; sex of the
patient. The dependant variables included low
versus high FEV1/FVC ratio at rest and post-
bronchodilator treatment. The independent and
dependant variables were divided into binominal
variables as follows: FEV1/FVC low versus normal
pre- and post-BD; decreased AHR at the end of the
study period.Results
Five hundred and eighty patients were reviewed.
Of these, 198 children met all the inclusion criteria
and were included in the analysis.Table 1 Comparison of age and pulmonary function tes
versus treated study groups.
Untreated gro
Number of patients 50
Age at beginning (years 7SD) 8.571.4
Baseline
FEV1 85.978.4
(range) (81–98)
FEV1/FVC 90.374.8
Percentage change over time
FEV1 2.0272.5
FEV1/FVC 1.1471.3
FEV1 increase by 410% post-BD at end of the study
Yes 14(28)
No 36(72)
Low post-bronchodilator FEV1/VC ratio
Baseline 5(10)
End of study 14(28)
Low FEV1/FVC ratio
Baseline 5(10)
End of study 5(10)
FVC and FEV1 : Predicted values (liters) 7SD.Relevant percentageAsthmatic children who used anti-inflammatory
inhalers (steroids) on a regular basis (treated
group) comprised 148 children. The group defined
as mild intermittent asthma (untreated group)
consisted of 50 children.Pulmonary function tests
At the start of the study FEV1, FVC and FEV1/FVC
were better in the untreated group than in the
treated group (Table 1). By the end of the study the
FVC improved by an average of 8.8% in the treated
group compared to 4.7% in the untreated group
(Po0:001). The FEV1 improved by an average of
10% in the treated group compared to 2% in the
untreated group (Po0:001). The FEV1/FVC ratio in
the treated group improved by and overage of 7.7%
in contrast to an average decrease of 1.1% in the
untreated group (Po0:0001).
Bronchial hyper responsiveness defined as an
increase in FEV1 of greater than 10% post-bronch-
odilator decreased significantly in the treated
group compared to the untreated group.
Bronchial hyper responsiveness decreased from
34% to 28% in children from the untreated group by
the end of the 5-year period, whereas in the
treated group it decreased from 54% to 41%.ts data at the baseline and end of study in untreated
up Treated group P value
148
8.870.5 0.15
73714.2 0.0001
(65–78)
80.375 0.001
1075 0.001
7.775.5 0.0001
61(41.2) 0.13
87(58.8)
52(35.1) 0.009
31(20.9)
41(27.7) 0.8
38(25.7)
s appear in parenthesis.
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the low FEV1/FVC post-bronchodilator was mark-
edly increased over the 5-year period in the
untreated group compared to the treated group.
In the treated group the FEV1/FVC ratio post-
bronchodilator decreased from 35% to 20.9%
(Po0:009%). In contrast, in the untreated group
the number of children with low FEV1/FVC post-
bronchodilator increased from 10% to 28% by the
end of the study period.Regression analysis
A multivariate analysis with low FEV1/FVC ratio at
end of the study and low post-BD FEV1/VC ratio was
also performed. It illustrated that the most
significant independent variable affecting low
post-BD FEV1/VC ratio at end of the study was
male sex. With respect to low FEV1/VC ratio at end
of the study, the Male: Female variable gave an
odds ratio of 2.4 with 95% confidence interval (CI)
between 1.13 and 5.09. The Male:Female odds
ratio with respect to low post-BD FEV1/VC ratio was
2.38 with CI between 1.09–5.18 post-treatment
with bronchodilator. Having a feline pet was the
most significant variable affecting low FEV1/VC
ratio with odds ratio of 2.58 (95% CI between 1.25
and 4.95) (Table 2).
No significant differences were noted in growth,
height or weight percentiles in either of the two
groups and atopy rates were similar.Table 2 Adjusted odds ratio and 95% confidence in
bronchodilator FEV1/VC ratio and low FEV1/VC ratio at th
Low FEV1/VC post-BD a
the end of the study
Baseline FEV1/VC 1.2(0.83–1.73)
End of study FEV1/VC 1.06(0.69–1.63)
End of study decrease AHR 1.4(0.49–3.93)
End of study increase AHR 0.31(0.02–4.8)
Parental smokers 1.16(0.84–1.6)
Positive skin test HDM 1.07(0.81–1.4)
Positive skin test 1.15(0.89–1.47)
Feline pet at home 1.58(0.81–3.09)
Canine pet at home 1.5(0.53–2.1)
Asthma onset before 3 years of
age
1.22(0.89–1.66)
Male sex 2.41(1.13–5.09)
AHR—Airway hyper responsiveness.
HDM—House dust mite.Discussion
Our results show that a group of patients with more
severe asthma using long-term inhaled steroids had
a significant reduction in the prevalence of airway
remodeling. The opposite was true in children with
mild intermittent asthma which did not use inhaled
steroids on a regular basis. This group demon-
strated a considerably higher incidence of airway
remodeling at the end of the study when compared
to the beginning. It was previously reported that
airway remodeling is related to the clinical and
functional severity of the asthma.8,9
In this study, the incidence of evidence of airway
remodeling in patients with mild intermittent
asthma more than doubled. By the end of the
study 28% of children with mild intermittent
asthma demonstrated a low FEV1/FVC ratio post-
bronchodilator. Conversely, the percentage of
children in the treatment group with evidence of
airway remodeling dropped from 35% to 20% by the
conclusion of the study. Paradoxically, we noted
that by the end of the study, the percentage of
subjects with mild intermittent asthma with evi-
dence of airway remodeling was higher than in the
group consisting of children with more severe
asthma. A recent study11 showed that the remodel-
ing process tends to become irreversible unless
inhibited by inhaled steroid therapy.
Our study followed children from a young age
until adolescence. The impact of atopy, parental
smoking and the presence of pets was analyzed but
did not explain differences noted in the incidenceterval for risk factors associated with low post-
e end of the study.
t P value Low FEV1/VC at the end
of the study
P value
0.2 1.12(0.56–2.19) 0.44
0.46 1.78(0.9–3.53) 0.07
0.36 2.77(0.675–11.4) 0.1
0.42 3.66(0.225–59.8) 0.39
0.21 1.5(0.75–3.08) 0.16
0.36 0.99(0.49–1.98) 0.56
0.16 1.07(0.51–2.22) 0.51
0.19 2.48(1.25–4.95) 0.008
0.5 1.49(0.86–2.57) 0.08
0.12 1.28(0.92–1.78) 0.07
0.01 2.38(1.09–5.18) 0.02
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groups. In our study, male sex was found to have
a higher chance of developing airway remodeling
and airway obstruction. This difference may be due
to the greater severity of disease among young boys
with asthma12 as compared with their female
counterparts.
Noncompliance is common in asthma patients13
and may explain why some children who were in
the group that used inhaled steroids continue to
deteriorate. Sophisticated experimental methods
are required in order to determine compliance and
adherence to chronic therapy in children. Recently
it was shown that even with adequate supervision
and frequent inspections it is difficult to monitor
therapeutic compliance.14
A study by Covar et al.10 demonstrated that a
significant number of children with mild intermit-
tent asthma demonstrated a reduction in post-
bronchodilator FEV1 values despite treatment with
budesonide or nedocromil. Because there was a
higher percentage of reduction in lung function
noted at earlier ages, the investigators believed
that a reduction of lung function begins early in the
course of asthma and does not proceed uniformly
over time.
Overall, we noted an increase in the number of
children with a low post-bronchodilator FEV1/FVC
ratio in the mild untreated group compared with
the treated group. This finding supports the
hypothesis that asthma patients who do not receive
preventative anti-inflammatory treatment have an
increased risk of airway remodeling. Furthermore,
inhaled corticosteroid treatment tends to prevent
or reduce airway remodeling in pediatric asthma
patients. All the children in the untreated group
were asymptomatic except for occasional episodes
of shortness of breath and/or exercise induced
asthma. All of them benefited from bronchodilators
as needed.
Asthma treatment is designed to control symp-
toms and prevent long-term damage (airway
remodeling). While it appears that the first goal is
met to a large extent, the latter aim is more
challenging especially with regards to patients with
mild intermittent asthma. This raises the question
of whether current treatment protocols for mild
intermittent asthma are adequate. The feeling of
the authors is that in all probability, a place exists
for preventative inhaled corticosteroid therapy inmild intermittent disease. We recommend that
mild intermittent asthma patients undergo regular
pulmonary function testing and that if any dete-
rioration is detected in the FEV1/FVC ratio post-
bronchodilators, preventative inhaled corticoster-
oid therapy should be initiated.Reference
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